China Health Group has successfully finished the Clinical Study of new drug Chiglitazar in Phase II in Shenzhen on July 23. There are many famous experts like Xiaofeng Lv of GENERAL HOSPITAL OF THE CHINESE PLA BEIJING REGION attending the conference.
Venturepharm-TX is a sub company of China Health Group , which is a professional company on drug development and clinical research of Diabetes Mellitus. After two years, XN-VPS has successfully finished the Clinical Study of XGLT in Phase II. Chiglitazar, a new non-thiazolidinedione insulin sensitizer, is independently developed by China and gained finance from our national ¡°fifteen¡± project. Venturepharm-TX has operated DM, osteoporosis and over 40 clinical study projects on the related disease. Owning good cooperation with 95% professional clinical drug study institutions on endocrine and many famous domestic and foreign experts, Venturepharm-TX has provided each project the perfect security and progress.